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Summary
Brain edema is associated with a variety of neuropathological con-
ditions such as brain trauma, ischemic and hypoxic brain injury, cen-
tral nervous system infection, acute attacks of multiple sclerosis, and
brain tumors. A common finding is an inflammatory response, which
may have a significant impact on brain edema formation. One criti-
cal event in the development of brain edema is blood-brain barrier
(BBB) breakdown, which may be initiated and regulated by several
proinflammatory mediators (oxidative mediators, adhesion mole-
cules, cytokines, chemokines). These mediators not only regulate the
magnitude of leukocyte extravasation into brain parenchyma, but
also act directly on brain endothelial cells causing the loosening of
junction complexes between endothelial cells, increasing brain endo-
thelial barrier permeability, and causing vasogenic edema. Here we
review junction structure at the BBB, the e¤ects of pro-inflammatory
mediators on that structure, and focus on the e¤ects of chemokines
at the BBB. New evidence indicates that chemokines (chemoattrac-
tant cytokines) do not merely direct leukocytes to areas of injury.
They also have direct and indirect e¤ects on the BBB leading to
BBB disruption, facilitating entry of leukocytes into brain, and in-
ducing vasogenic brain edema formation. Chemokine inhibition
may be a new therapeutic target to reduce vasogenic brain edema.
Keywords: Blood-brain barrier; monocyte chemoattractant pro-
tein; CCL2; tight junctions.
Introduction
Inflammation and proinflammatory mediators play
an essential role in edema development in a variety of
neuropathological conditions such as brain trauma, is-
chemic or hypoxic brain injury, central nervous system
(CNS) infection (HIV infection, tuberculosis, or bacte-
rial meningitis), acute attacks of multiple sclerosis, and
brain tumors [12, 19, 21, 29, 45, 49, 64]. Brain edema in
all of these conditions is mostly classified as vasogenic
with extracellular water accumulation resulting from
blood-brain barrier (BBB) disruption and massive in-
filtration of leukocytes. The critical pathophysiologi-
cal mechanism in vasogenic brain edema formation is
BBB disruption, characterized by activation of brain
endothelial cells followed by loosening of junctional
complexes between those cells and increased barrier
permeability. This is accompanied by leukocyte re-
cruitment into the brain parenchyma and extrava-
sation of plasma proteins [64]. We reviewed current
knowledge on the ability of proinflammatory media-
tors to regulate BBB permeability and how they con-
tribute to brain edema formation.
Unique properties of the BBB and cerebral endothelium
Under basal conditions, the BBB acts as a highly
specialized structural and biochemical barrier that reg-
ulates the entry of blood-borne molecules into brain
and preserves ionic homeostasis within the brain mi-
croenvironment [53, 67]. The BBB is composed of a
specialized tight adherent microvascular endothelium
and glial cell elements (astrocytes and microglia) along
the entire endothelial abluminal surface [48]. Specific
properties of the brain endothelial barrier are the pres-
ence of continuous strands of intercellular junction
complexes that almost completely seal the paracellular
cleft between adjacent endothelial membranes [4, 53].
Two morphologically distinct structural units occur in
these intercellular junctional complexes: tight junc-
tions (TJs) and adherens junctions [25].
TJs at the BBB are composed of an intricate combi-
nation of transmembrane integral proteins and several
cytoplasmic-accessory proteins classified into 2 major
groups: postsynaptic density (PDZ) domain contain-
ing proteins, and non-PDZ proteins [9, 25]. The major
structural proteins of TJs are: (i) claudins (claudin-1,
-5, -11), tissue-specific proteins that form the primary
seal of TJ, (ii) occludin, an integral membrane protein
involved in regulation of electrical resistance across the
BBB and paracellular permeability, and (iii) junctional
adhesion molecules (JAMs; JAM-1, -2, -3), single
membrane-spanning proteins that belong to the immu-
noglobulin superfamily, which are mostly involved
in leukocyte-endothelial cell interaction and leukocyte
transmigration [9, 13, 25, 32, 40]. The TJ accessory
proteins are multi-domain cytoplasmic molecules that
form structural support for the TJ and are involved in
signal transduction. The TJ PDZ-containing proteins
are zonula occludens proteins (ZO-1, ZO-2, ZO-3)
and AF6. The group of non-PDZ TJ proteins contains
cingulin, 7H6, and atypical protein kinase C [9, 13, 25,
40].
Although the proteins of the TJ complex ultimately
determine the barrier properties of endothelial cells,
the adherens junction (AdJ) proteins mediate initial
adhesion between endothelial cells and modulate TJ
permeability [59]. The adherens junction complex is
composed of a cadherin-catenin complex (Ve cadherin
bound to b-catenin, plakoglobin, and a-catenin) and
associated proteins (e.g., p 120 protein) [42, 59]. Both
TJ and AdJ proteins are linked to cytoskeletal pro-
teins. Actin, the primary cytoskeletal protein, has
both structural and dynamic roles within cells [57, 62].
BBB opening: morphological aspects
At the functional level, the junctional complexes
result in a high transendothelial electrical resistance,
typically 1500–2000 W.cm2, making the BBB a unique
selective permeability barrier [25]. Alterations in brain
endothelial junctional complexes can result in in-
creased in BBB permeability. At the cellular level,
BBB ‘‘opening’’ is manifested by intercellular gap for-
mation, changes in cell shape, reorganization of actin
microfilament bundles, and redistribution of endothe-
lial junction proteins. The typical morphological pat-
tern of actin reorganization involves increased stress fi-
ber density and a reduction or loss of the cortical actin
band. This pattern occurs in parallel with and/or could
cause spatial redistribution of both AdJ and TJ struc-
tures. There is decreased association of the cadherin/
catenin complex with a shift to intracellular pools, dis-
organization of occludin on the endothelial surface
with a loss of ZO-1, and increased association of occlu-
din, ZO-1, and ZO-2 with actin filaments, which shifts
these proteins to an insoluble cytosolic pool [15, 20, 63,
66]. The loss of adherence between brain endothelial
cells, accompanied by conformational changes in TJ
proteins and increased intercellular forces, widens the
gap between brain endothelial cells and facilitates ex-
travasation of leukocytes and plasma proteins into
the brain parenchyma. Alterations in brain endothelial
junctions represent a basic substrate for developing
vasogenic brain edema.
Inflammation, proinflammatory mediators, and BBB
opening
In conditions such as multiple sclerosis, AIDS-
associated encephalopathy, and meningitis/menin-
goencephalitis, inflammation is considered a primary
cause of brain damage [26, 39, 46]. On the other
hand, in conditions such as Alzheimer’s disease and
stroke, inflammation can induce secondary brain in-
jury by aggravating the initial insult [16, 22]. In all of
these cases, there are the classic hallmarks of brain in-
flammation: BBB breakdown, edema formation, tissue
infiltration by peripheral blood cells, activation of
immunocompentent cells, and intrathecal release of
numerous immune mediators such as interleukins and
chemotactic factors [33]. Common pathological find-
ings are the presence of many leukocytes (monocytes
or neutrophils) and activated microglial cells in the
brain parenchyma, and a loss of immunostaining for
most TJ proteins (occludin, ZO-1, claudin-5, or ZO-2)
at the BBB [6, 26, 31, 43]. This may be an indicator of
TJ protein redistribution/reorganization at the junc-
tion complex.
Proinflammatory mediators play a crucial role in
regulation of CNS inflammation as well as in modulat-
ing BBB permeability. For example, proinflammatory
cytokines (IL-1a, IL-1b, TNF-a, IL-6, GM-CSF) pro-
duced by invading leukocytes, activated endothelial
cells, or other components associated with the BBB
(astrocytes or perivascular macrophages), regulate the
magnitude and persistence of inflammatory brain reac-
tions [5, 46, 68]. But those factors also directly through
their own receptors, or indirectly via other mediators,
participate in BBB disruption. IL-1b and TNF-a in-
crease BBB permeability under in vitro and in vivo
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conditions, altering endothelial cell junction com-
plexes leading to the development of local inflamma-
tory responses and edema formation [5, 18, 68]. Neu-
tralizing antibodies to these cytokines can diminish
brain edema formation [24, 44].
Oxidative stress and mediators of oxidative injury
(superoxide, hydrogen peroxide, peroxynitrite, nitric
oxide, eicosanoids) are a second group of factors impli-
cated in reducing TJ integrity and causing edema
formation [23, 27]. Oxidative mediators can directly
trigger a signal cascade with one end-point being a re-
distribution of TJ and AdJ proteins and reorganiza-
tion of the endothelial actin cytoskeleton. Oxidative
mediators can also regulate the expression/activity of
other proinflammatory mediators and, in this way,
‘‘open’’ the BBB [18, 27].
Adhesion molecules (ICAM-1, VCAM-1) and
selectins can also alter TJ complexes by regulating
leukocyte/endothelial cell interactions. Those interac-
tions may trigger expression of other proinflammatory
mediators or intracellular signal cascades that regulate
BBB integrity [14]. Leukocytes can also contribute
to the persistence of increased vascular permeability
via interactions with endothelial cells and the release
of proinflammatory mediators, or by production of
proinflammatory mediators in the brain parenchyma
[11, 38, 47]. One particularly interesting group of
proinflammatory mediators that contribute to altera-
tions in BBB permeability are chemokines. In recent
years, the role of these chemoattractant cytokines in
CNS inflammation has emerged.
Chemokine-regulated BBB opening: role in brain
edema formation
Chemokines are proinflammatory mediators in-
volved in the selective driving of leukocytes into brain
parenchyma. Enhanced perivascular chemokine ex-
pression is found in many pathological settings accom-
panied by inflammation, providing a chemoattractant
gradient for leukocyte influx [41, 52].
Chemoattractant cytokines (chemokines) are a novel
superfamily of structurally-related proinflammatory
peptides (@70 to 90 amino acids) of low molecular
weight (8 to 10 kDa). They have been divided into
4 classes on the basis of the positions of the first 2
conserved cysteine residues (C) and the number of
intervening amino acids (X) between them (e.g., C,
Fig. 1. Intracerebroventricular administration of CCL2 increases BBB permeability and brain edema formation. (A) Distribution of FITC-
albumin in brain coronal sections; (B) permeability surface (PS ) area products for FITC albumin; and (C) brain water content in CCL2- and
saline-treated control mice. Measurements were made 6, 12, 24, and 48 hours after a single CCL2 dose (25 mg) or after a 3-day (5 mg/hr) or
7-day (2.5 mg/hr) chronic infusion. PS products were measured in ipsilateral (IH ) and contralateral (CH ) hemispheres. Brain water content
measurements are of the whole brain. Values are meanG SD. * indicates significant di¤erence between CCL2-treated mice and control animals
at the p < 0:001 level. Scale bar ¼ 1000 mm
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CC, CXC, and CXXXC subfamilies) [41, 52, 69].
These subfamilies further exhibit functional di¤er-
ences. For example, CXC chemokines target mainly
neutrophils, while CC chemokines primarily target
monocytes/macrophages, eosinophils, and basophils,
while CXC and CC chemokines invoke responses
in lymphocytes [51, 69]. All chemokines mediate their
e¤ects by binding to 7-transmembrane G protein-
coupled receptors related to rhodopsin. Some of the
functional consequences of chemokine-receptor inter-
actions are alterations in integrin adhesiveness, cell mi-
gration, polarization, and proliferation, as well as in
gene expression [36, 51]. The discovery that parenchy-
mal cells (astrocytes, oligodendroglial cells, and micro-
glia in the CNS) and endothelial cells (including brain
endothelial cells) express chemokine receptors signifi-
cantly extended the possible functions of chemokines
in inflammation and other (patho)physiological condi-
tions [1, 2]. One of these novel functions is that chemo-
kines can regulate BBB permeability.
The chemokine CXCL8 (IL-8) has already been
shown to contribute to brain edema formation during
ischemia/reperfusion injury. Thus, Matusmoto and
colleagues [35] showed that adding an IL-8 neutraliz-
ing antibody significantly reduced edema formation in
rabbit. In addition to IL-8, several studies examining
the e¤ect of IL-1b on BBB permeability have found a
strong correlation between IL-1b-induced expression
of chemokines, such as CINC1 and MIP-2 (CXCL2),
and increased BBB permeability. Neutralizing anti-
bodies to MIP2 and CINC1 can prevent BBB break-
down [3, 7].
A well-studied example of the e¤ect of chemokines
on BBB permeability is the action of monocyte chemo-
attractant protein-1 (MCP-1, CCL2). CCL2 belongs
to the CC subfamily of chemokines and is involved
in recruitment of monocytes/macrophages and acti-
vated lymphocytes into brain during neuropatholog-
ical states [37]. CCL2 is highly expressed in the peri-
vascular space and brain parenchyma during CNS
inflammation, but it is also present in cerebrospinal
fluid in several CNS inflammatory states (stroke, men-
ingitis, multiple sclerosis) [8, 30, 34, 56, 58]. Expression
of CCL2 receptor CCR2 was found on components of
BBB (brain endothelial cells and astrocytes), suggest-
ing that CCL2 might not only act on leukocyte recruit-
ment but could also participate in regulation of the in-
flammatory response at the level of the BBB.
Our laboratory has shown that CCL2 (in mmol con-
centrations) in brain parenchyma or in cerebrospinal
fluid can increase BBB permeability several fold (as
measured by the permeability surface area product for
fluorescein isothiocyanate-labeled albumin) and also
induce brain edema formation (Fig. 1). In areas of
BBB leakage, immunostaining for TJ proteins (occlu-
din, ZO-1, ZO-2, claudin-5) was extensively reduced
and there was intense infiltration of leukocytes [61].
There are 2 possible explanations of how CCL2
changes BBB permeability and causes vasogenic brain
edema formation.
The e¤ects of CCL2 on BBB permeability could be
direct by acting on brain endothelial cells, or indirect
by inducing production of other proinflammatory me-
diators by endothelial cells, astrocytes, or leukocytes.
Evidence indicates that CCL2 acts via both mecha-
nisms. In vitro treatment of brain endothelial cell
monolayers or an in vitro model of BBB (co-culture
of brain endothelial cells and astrocytes) with recombi-
nant CCL2 exerts the same morphological and bio-
chemical changes. Thus, TJ proteins are redistributed
from a TritonX-100 soluble to a TritonX-100 insoluble
fraction (potentially reflecting internalization of TJ
proteins into a cytoplasmic compartment) and there is
a loss or fragmentation of TJ protein staining [60, 61].
These biochemical and morphological alterations are
absent if the CCL2 receptor CCR2 is not present on
the brain endothelial cells [60, 61]. The e¤ects of
CCL2 on BBB permeability in vivo are abolished if
the CCR2 receptor is deleted, pinpointing that CCL2
alters BBB permeability directly via its own CCR2
receptor.
Indirect e¤ects of CCL2 on BBB permeability
may involve regulation of leukocyte recruitment
and/or regulation of the expression of proinflam-
matory mediators. We have found that depletion of
circulating monocytes and activated macrophages by
liposomally-encapsulated clodronate attenuates the ef-
fect of CCL2 on BBB permeability in vivo [61]. This
implies that leukocytes are one of the factors contri-
buting to BBB breakdown. Other factors may include
proinflammatory factors such as VEGF and IL-1,
which are significantly reduced in CCL2 knockout
mice undergoing middle cerebral artery occlusion [28].
These results on CCL2, which may also apply to
other chemokines, indicate a potential key role in me-
diating BBB breakdown during inflammation. CCL2
may not only direct leukocytes to sites of injury, but it
may facilitate leukocyte migration into brain paren-
chyma by enhancing BBB permeability. Such BBB
breakdown may also result in vasogenic edema.
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Molecular mechanisms underlying regulation of
permeability by CCL2
In general, several signal pathways regulate BBB
permeability. For alterations in actin cytoskeleton ar-
chitecture, prominent roles are proposed for: (i) Ca2þ/
calmodulin- and Rho/Rho kinase-dependent path-
ways, primarily acting on the activity of myosin light
chain kinase in order to facilitate actin and myosin
light chain interaction and stress fiber formation. (ii)
Phosphorylation of TJ and AdJ proteins by protein
kinase C isoforms, tyrosine kinase lyn, serine kinase,
and protein tyrosine phosphatase. (iii) Under some
circumstances, proteolytic degradation of junctional
constituents by matrix metalloproteinases (MMP-2,
MMP-9) leading to the loss of TJs and AdJs and in-
creased BBB permeability [10, 17, 18, 20, 50, 54, 65].
Chemokines, like other proinflammatory mediators,
have a prolonged e¤ect on the brain endothelial bar-
rier denoted as thrombin type and characterized by in-
tercellular widening for more than 30 minutes and
specific activation of Rho/Rho kinase pathways. Two
independent studies on 2 di¤erent types of model sys-
tems have shown that chemokines CXCL8 and CCL2
induce activation of Rho/Rho kinase with stress fiber
formation [55, 60]. Further, Stamatovic et al. [60]
found that Rho/Rho kinase not only altered the actin
cytoskeletal organization but also had a significant im-
pact on TJ protein complexes between brain endothe-
lial cells. Diminishing Rho activity by transfection with
dominant negative mutant of Rho stabilized brain en-
dothelial barrier integrity. This led to the conclusion
that Rho is a ‘‘nodal point’’ in brain endothelial inter-
cellular signaling directed to alter junction complex of
brain endothelial cells. Future investigation is needed
to elucidate how Rho induces the phosphorylation
and redistribution of TJ proteins.
Conclusion
Proinflammatory mediators, including chemokines,
have a significant impact on brain edema formation
in a variety of neuropathological conditions. Experi-
ments examining CCL2, studied as a prototype for
chemokine activity, show e¤ects on leukocyte extrava-
sation not only through directing leukocytes into the
brain parenchyma but also by enhancing BBB disrup-
tion. CCL2 a¤ects brain endothelial cells directly (via
CCR2 receptors) and indirectly (via production of
other proinflammatory agents). CCL2-induced BBB
disruption may contribute to plasma protein extra-
vasation and vasogenic brain edema as well as aggra-
vating leukocyte influx. Chemokines are emerging
as powerful factors controlling inflammation-induced
brain edema. Elimination of chemokine activity via
newly developed chemokine receptor antagonists of-
fers a new potential avenue for the treatment of vaso-
genic brain edema.
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